Skip to main content

Table 4 Prognostic/predictive factors at multivariate analysis

From: Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

Survival (N=136)

HR

95% CI

Wald-p

Age

> median

1.64

1.08-2.48

0.0199

EPHA2

High vs. Low

1.67

1.05-2.63

0.0287

EREG

High vs. Low

0.38

0.21-0.66

0.0006

AREG/KRAS interaction

7.98

2.98-21.40

<.0001

AREG high in KRAS mutant vs

   

AREG high in KRAS wild type

   

AREG

   

AREG high vs. low for KRAS wild type

0.17

0.08-0.34

<.0001

AREG high vs. low for KRAS mutant

1.33

0.67-2.61

0.4165

KRAS

   

KRAS mutant vs. wild type for AREG high

1.49

0.90-2.45

0.1184

KRAS mutant vs. wild type for AREG low

0.19

0. 08–0.43

<.0001